Document Type : Original Article
Authors
- . Amir-Mohammad Armanian 1
- . Alireza Sadeghnia 1
- . Maryam Hoseinzadeh 2
- . Maryam Mirlohi 3
- . Awat Feizi 4
- . Nima Salehimehr 5
- . Moloud Torkan 2
- . Zahra Shirani 2
1 Department of Pediatrics, Division of Neonatology, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Food Technology, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Epidemiology and Biostatistics, Endocrinology and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
5 Department of Health, Almahdi University, Isfahan, Iran
Abstract
Objective: This study was designed to compare the efficacy and safety of enteral
supplementation of a prebiotic mixture (SCGOS/LCFOS) on faecal microbiota in very
premature infants who fed exclusively with human-milk.
Methods: This double‑center randomized control trial was conducted from December
2012 to November 2013 in the tertiary Neonatal Intensive Care Units of the Isfahan
University of Medical Sciences. Fifty preterm infants (birth weight ≤1500 g who
were not fed with formula) were randomly allocated to have enteral (tube feeding)
supplementation with a prebiotic mixture (SCGOS/LCFOS; 9:1) or receive no prebiotics.
Findings: The primary outcome (e.g., the effect of the prebiotic mixture on fecal
microbiota pattern) was clearly different between the two groups. Despite greater
coliforms colony counts in first stool cultures in the prebiotic group (Group P)(P = 0.67),
coliforms were significantly lower in the third stool cultures in the Group P (P < 0.001).
Furthermore, despite the much higher Lactobacillus colony counts, in the first
stool cultures, in the control group (Group C) (P = 0.005); there was a trend toward
significantly increased Lactobacillus colony counts in the Group P during the study,
but the difference between Lactobacillus colony counts, in the third stool cultures,
between two groups was no longer statistically significant(P = 0.11). Interestingly, the
median length of hospital stay was significantly less in the Group P (16 [12.50–23.50]
vs. 25 [19.50–33.00] days; P = 0.003).
Conclusion: This suggests that it might have been “the complete removal of formula” which
manifests a synergistic effect between nonhuman neutral oligosaccharides (prebiotics)
and human oligosaccharides, which in turn, led to the rapid growth of beneficial
Lactobacillus colonies in the gut of breast milk‑fed preterm infants, while decreasing
the number of pathogenic coliforms microorganisms. Therefore, further studies with
larger sample sizes are recommended to investigate the issue.
Keywords
in full‑term neonates: A systematic review of randomized
controlled trials. Arch Pediatr Adolesc Med 2009;163:755‑64.
2. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics.
Pediatrics 2010;126:1217‑31.
3. Westerbeek EA, van den Berg JP, Lafeber HN, Fetter WP,
Boehm G, Twisk JW, et al. Neutral and acidic oligosaccharides
in preterm infants: a randomized, double‑blind,
placebo‑controlled trial. Am J Clin Nutr 2010;91:679‑86.
4. Westerbeek EA, van den BergA, Lafeber HN, KnolJ, FetterWP,
van ElburgRM. The intestinal bacterial colonisation in preterm
infants: A review of the literature. Clin Nutr 2006;25:361‑8.
5. Van der Zwet WC, Kaiser AM, van Elburg RM, Berkhof J,
Fetter WP, Parlevliet GA, et al. Nosocomial infections in a
Dutch neonatal intensive care unit: Surveillance study with
definitions for infection specifically adapted for neonates. J Hosp Infect 2005;61:300‑11.
6. Field CJ. The immunological components of human milk
and their effect on immune development in infants. J Nutr
2005;135:1‑4.
7. Vos AP, M’Rabet L, Stahl B, Boehm G, Garssen J.
Immune‑modulatory effects and potential working
mechanisms of orally applied nondigestible carbohydrates.
Crit Rev Immunol 2007;27:97‑140.
8. BodeL. Recent advances on structure, metabolism, and function
of human milk oligosaccharides. J Nutr 2006;136:2127‑30.
9. Boehm G, Stahl B, Mattila‑Sandholm T, Saarela M.
Oligosaccharides. Functional Dairy Products. 2003:203-43.
ISBN 1-85573-584-9.
10. Willemsen LE, Koetsier MA, van Deventer SJ, van Tol EA.
Short chain fatty acids stimulate epithelial mucin 2 expression
through differential effects on prostaglandin E(1) and E(2)
production by intestinal myofibroblasts. Gut 2003;52:1442‑7.
11. Arslanoglu S, Moro G, Schmitt J, Tandoi L, Rizzardi S,
Boehm G. Early dietary intervention with a mixture of
prebiotic oligosaccharides reduces the incidence of allergic
manifestations and infections during the first two years of
life. J Nutr 2008;138:1091.
12. Fanaro S, Boehm G, Garssen J, Knol J, Mosca F,
Stahl B, et al. Galacto‑oligosaccharides and long‑chain
fructo‑oligosaccharides as prebiotics in infant formulas: A
review. Acta Paediatr Suppl 2005;94:22‑6.
13. Boehm G, Jelinek J, Stahl B, van Laere K, Knol J, Fanaro S,
et al. Prebiotics in infant formulas. J Clin Gastroenterol
2004;38 6 Suppl: S76‑9.
14. Bruzzese E, Volpicelli M, Squeglia V, Bruzzese D, Salvini F,
Bisceglia M, et al. A formula containing galacto‑and
fructo‑oligosaccharides prevents intestinal and extra‑intestinal
infections: An observational study. Clin Nutr (Edinb, Scotl)
2009;28:156.
15. Boehm G, Lidestri M, Casetta P, Jelinek J, Negretti F,
Stahl B, et al. Supplementation of a bovine milk formula
with an oligosaccharide mixture increases counts of faecal
bifidobacteria in preterm infants. Arch Dis Child Fetal
Neonatal Ed 2002;86:F178‑81.
16. Kapiki A, Costalos C, Oikonomidou C, Triantafyllidou A,
LoukatouE, PertrohilouV. The effect of a fructo‑oligosaccharide
supplemented formula on gut flora of preterm infants. Early
Hum Dev 2007;83:335‑9.
17. Costalos C, Kapiki A, Apostolou M, Papathoma E. The effect
of a prebiotic supplemented formula on growth and stool
microbiology of term infants. Early Hum Dev 2008;84:45‑9.
18. Modi N, Uthaya S, Fell J, Kulinskaya E. A randomized,
double‑blind, controlled trial of the effect of prebiotic
oligosaccharides on enteral tolerance in preterm
infants (ISRCTN77444690). Pediatr Res 2010;68:440‑5.
19. Riskin A, Hochwald O, Bader D, Srugo I, Naftali G,
KugelmanA, et al. The effects of lactulose supplementation to
enteral feedings in premature infants: A pilot study. J Pediatr
2010;156:209‑14.
20. Westerbeek EA, Slump RA, Lafeber HN, Knol J, Georgi G,
Fetter WP, et al. The effect of enteral supplementation of
specific neutral and acidic oligosaccharides on the faecal
microbiota and intestinal microenvironment in preterm
infants. Eur J Clin Microbiol Infect Dis 2013;32:269‑76.
21. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J
Respir Crit Care Med 2001;163:1723‑9.
22. Knol J, Boehm G, Lidestri M, Negretti F, Jelinek J, Agosti M,
et al. Increase of faecal bifidobacteria due to dietary
oligosaccharides induces a reduction of clinically relevant
pathogen germs in the faeces of formula‑fed preterm infants.
Acta Paediatr Suppl 2005;94:31‑3.
23. Moro G, Minoli I, Mosca M, Fanaro S, Jelinek J, Stahl B,
et al. Dosage‑related bifidogenic effects of galacto‑ and
fructooligosaccharides in formula‑fed term infants. J Pediatr
Gastroenterol Nutr 2002;34:291‑5.
24. Srinivasjois R, Rao S, Patole S. Prebiotic supplementation
in preterm neonates: Updated systematic review and
meta‑analysis of randomised controlled trials. Clin Nutr
2013;32:958‑65
)